Abstract
Repeat expansions in chromosome 9 open reading frame 72 (C9ORF72) are an important cause of both motor neuron disease (MND) and frontotemporal dementia (FTD). Currently, little is known about factors that could account for the phenotypic heterogeneity detected in C9ORF72 expansion carriers. In this study, we investigated 4 genes that could represent genetic modifiers: ataxin-2 (ATXN2), non-imprinted in Prader-Willi/Angelman syndrome 1 (NIPA1), survival motor neuron 1 (SMN1), and survival motor neuron 2 (SMN2). Assessment of these genes, in a unique cohort of 331 C9ORF72 expansion carriers and 376 control subjects, revealed that intermediate repeat lengths in ATXN2 possibly act as disease modifier in C9ORF72 expansion carriers; no evidence was provided for a potential role of NIPA1, SMN1, or SMN2. The effects of intermediate ATXN2 repeats were most profound in probands with MND or FTD/MND (2.1% vs. 0% in control subjects, p= 0.013), whereas the frequency in probands with FTD was identical to control subjects. Though intermediate ATXN2 repeats were already known to be associated with MND risk, previous reports did not focus on individuals with clear pathogenic mutations, such as repeat expansions in C9ORF72. Based on our present findings, we postulate that intermediate ATXN2 repeat lengths may render C9ORF72 expansion carriers more susceptible to the development of MND; further studies are needed, however, to validate our findings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2421.e13-2421.e17 |
| Journal | Neurobiology of Aging |
| Volume | 35 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2014 |
Funding
This project was supported by National Institutes of Health grants R01 NS080882 , R01 NS065782 , R01 AG026251 , P01 AG017586 , P50 NS072187 , P50 AG016574 , P30 AG013854 , P30 AG012300 , P30 AG019610 , U01 AG006786 , the ALS Therapy Alliance , and the Consortium for Frontotemporal Dementia Research . Data collection at University of British Columbia is supported by Canadian Institutes of Health Research grant #179009 . Dr Van Blitterswijk is supported by the Milton Safenowitz Post-Doctoral Fellowship for ALS research from the ALS Association .
Keywords
- ATXN2
- Amyotrophic lateral sclerosis
- Ataxin-2
- C9ORF72
- Disease modifier
- Frontotemporal dementia
- Motor neuron disease
ASJC Scopus subject areas
- Clinical Neurology
- Geriatrics and Gerontology
- Aging
- General Neuroscience
- Developmental Biology